Comparing programmed death ligand 1 scores for predicting pembrolizumab efficacy in head and neck cancer
Kenneth Emancipator, Lingkang Huang, Deepti Aurora-Garg, Tricia Bal, Ezra E.W. Cohen, Kevin J. Harrington, Denis Soulières, Christophe Le Tourneau, Lisa Licitra, Barbara Burtness, Ramona F. Swaby
Topics & Concepts
PembrolizumabHead and neck squamous-cell carcinomaMedicineOncologyInternal medicineReceiver operating characteristicHead and neck cancerClinical trialImmunotherapyCancerCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsHead and Neck Cancer Studies